在COVID-19的治疗中Andrographis paniculata提取物与安慰剂对比:双盲随机对照试验
Puritat Kanokkangsadal1,2, Chatchai Mingmalairak3, Nichamon Mukkasombat1,2
1Department of Applied Thai Traditional Medicine, Faculty of Medicine, Thammasat University, Pathumthani 12120, Thailand.
Research in pharmaceutical sciences
|July 15, 2024
概括
在轻度病例中,Andrographis paniculata乙醇提取物 (APE) 并没有减少COVID-19的进展. 然而,APE显著缓解了头痛和嗅觉丧失症状,而不会引起不良影响.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 草药是一种草药.
背景情况:
- 安德罗格拉菲斯 (Andrographis paniculata) 已被建议用于缓解COVID-19的症状.
- 一项临床研究调查了其乙醇提取物 (APE) 的疗效和安全性.
研究的目的:
- 评估APE在无症状或轻度症状的COVID-19患者中的疗效和安全性.
- 在一项随机对照试验中,比较APE治疗与安慰剂.
主要方法:
- 进行了一项前性,双盲,随机对照试验.
- 患者接受APE (60毫克安德罗格拉福利德,每天3次,持续5天) 或安慰剂.
- 使用世卫组织的进展量表,症状评估和全球评估来评估有效性. 通过肝脏和功能测试来监测安全性.
主要成果:
- 165名患者完成了这项研究;83人接受了APE,82人接受了安慰剂.
- 在两组中,COVID-19症状在第5天显著改善,没有显著差异.
- 与安慰剂相比,APE在第一天显著减少了头痛,并在第二天显著减少了嗅觉损失.
- 在APE组中的80.7%的患者在5天内完全康复.
- 轻度腹是最常见的副作用,迅速消失. 没有观察到肝脏或脏毒性.
结论:
- 在轻度病例中,APE (180毫克/天5天) 并没有阻止COVID-19的进展.
- APE在缩短嗅觉损失症状方面表现出显著的益处.
- 治疗被发现是安全的,在5天的时间内没有观察到肝脏或脏毒性.
相关概念视频
Controls in Experiments
7.4K
When conducting an experiment, it is crucial to have control to reduce bias and accurately measure the dependent variables. It also marks the results more reliable. Controls are elements in an experiment that have the same characteristics as the treatment groups but are not affected by the independent variable. By sorting these data into control and experimental conditions, the relationship between the dependent and independent variables can be drawn. A randomized experiment always includes a...
7.4K
Panic Disorder
69
Panic disorder is an anxiety disorder characterized by recurrent and sudden minutes-long episodes of intense fear, known as panic attacks. These attacks may feel like heart attacks and often happen without warning or a specific cause. They can include symptoms such as rapid heart rate, shortness of breath, chest pain, trembling, sweating, dizziness, and a sense of helplessness. During a panic attack, individuals may feel as though they are experiencing a heart attack or are in a...
69


